A significant difference was observed between the GIS distributions for BRCA1/2-deficient ER + BC tumors and ovarian cancer tumors (p = 0.015; Fig. 1b), indicating that a separate threshold should be established for ER + BC tumors. This evidence concerns the gene ESR1 and breast cancer.